Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Oric Pharmaceuticals Inc ORIC

Healthcare Biotechnology
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ORIC)

ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones

GlobeNewswire 10 days ago

ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 6, 2026

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

GlobeNewswire December 5, 2025

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 5, 2025

ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025

GlobeNewswire December 5, 2025

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025

GlobeNewswire December 4, 2025

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025

GlobeNewswire December 3, 2025

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025

GlobeNewswire December 1, 2025

ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

GlobeNewswire November 24, 2025
View More News ››

Opinion & Analysis (NDAQ:ORIC)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ORIC)

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC): A Promising Oncolo

http://beyondspx.com/2024/08/02/oric-pharmaceuticals-inc-nasdaqoric-a-promising-oncology-player-overcoming-resistance/
MikeTester - August 3, 2024
View more Bullboard ››

Sekur Private Data Ltd.

Sekur Private Data Ltd.

Sekur Private Data Ltd. operates as a cybersecurity and internet privacy provider of Swiss hosted solutions for secure ...
View More »

Podcasts